Dr. Shimon Gross reports

DIAGNOSTEAR TECHNOLOGIES INC. ANNOUNCES RESULTS OF AGM

Diagnostear Technologies Inc. has released the results of its annual general meeting of shareholders held today. Shareholders approved all matters recommended by management, including:

• Setting the number of directors at five and electing Yaacov Michlin, Julia Reznick Zilberman, Karin Gurevitz, Igal Kohn and John Sinclair as directors of the company;
• The appointment of Doane Grant Thornton LLP as the company's auditor for the year ended Dec. 31, 2025, and for the ensuing year;
• Approve and confirm the company's rolling 10-per-cent equity incentive plan.

About Diagnostear Technologies Inc.

Diagnostear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. Diagnostear's TeaRx technology is a diagnostic platform intended for rapid, point-of-care testing (POCT) of ophthalmic pathologies through multiparameter analysis of non-invasively collected tear fluid. The first CE-IVD- and Israeli Ministry of Health-approved test based on the TeaRx platform is intended for diagnosis of dry eye syndrome (DES TeaRx Dry Eye). This product is not FDA (U.S. Food and Drug Administration) cleared yet. Beyond DES, Diagnostear is developing innovative tests based on the TeaRx platform for additional ophthalmic indications. Among others, Diagnostear's pipeline includes TeaRx Red Eye: the first test of its kind for differential assessment of adenoviral conjunctivitis, herpetic keratitis and allergic conjunctivitis.

We seek Safe Harbor.